| ［1］ Du X，Williams D A. Interleukin-11: Review of molecular,cell biology,and clinic use. Blood ,1997 ,89(11) :3897~3908
［2］ Wadhwa M, Thorpe R. Haematopoietic growth factors and their therapeutic use. Thromb Haemost, 2008, 99(5):863~873
［3］ Reynolds C H. Clinical efficacy of rhIL-11. Oncology, 2000, 14 (9 Suppl 8) :32~40
［4］ Jain A, Jain S K. PEGylation: an approach for drug delivery. Crit Rev Ther Drug Carrier Syst, 2008, 25(5):403~447
［5］ Takagi A, Yamashita N, Yoshioka T, et al. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. J Control Release, 2007, 119(3):271~278
［6］ 苗继红,王嘉玺,彭善云,等. 人白细胞介素11 基因在大肠杆菌中的克隆与表达.中国科学B辑,1995,25(6) :616~622
Miao J H, Wang J X, Peng S Y, et al.Science in China Series B, 1995, 25(6):616~622
［7］ Doherty D H, Rosendahl M S, Smith D J, et al. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor. Bioconjugate Chemistry，2005, 16: 1291~1298
［8］ Shaunak S, Godwin A, Choi J W, el al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nature Chemical Biology , 2006, 2(6):312~313
［9］ Czupryn M J ,Mccoy J M , Scoble H A. Structure-function relationships in human interleukin-11. J Biol Chem，1995,270: 978~985
［10］ Czupryn M, Bennett F, Dube J, et al. Alanine-scanning mutagenesis of human interleukin-11: Identification of regions important for biological activity. Ann NY Acad Sci, 1995, 762:152~164
|
